DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
DataMEDS says HHS policy changes also allow its distribution division to support compliant bulk drug substance and API supply.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DataMEDS AI (NASDAQ:MEDS) announced that subsidiary Corexa Health entered into a commercial supply agreement covering six peptides recommended by an FDA advisory committee.
The peptides are BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. The FDA's Pharmacy Compounding Advisory Committee recommended them at its July 23–24, 2026 meeting. Corexa Pharmacy intends to begin dispensing compliant compounded peptide prescriptions in November 2026.
DataMEDS plans to use the Health Lives Here mobile application to collect and report safety data under the HHS Enforcement Discretion Policy published October 30, 2026. The company says recent HHS policy changes allow Corexa Pharmacy to dispense compounded versions of the six peptides. These compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or efficacy.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointCorexa Health signed a commercial supply agreement covering six peptides recommended by the FDA advisory committee.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Corexa Pharmacy intends to begin dispensing compliant compounded peptide prescriptions in November 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.DataMEDS plans to collect and report safety data through its Health Lives Here application.
Negative
- None.
News Explained
DataMEDS reports that Corexa has entered an agreement for commercial supply of bulk drug substance and API for the six peptides—an input-supply arrangement; patient dispensing remains planned for
Details
Market Reaction – MEDS
On Nov 2, the day this news came out, the latest delayed price for MEDS is 0.47% below the previous close. Argus tracked a peak move of +7.4% during the session. Our momentum scanner has recorded 9 alerts for this stock so far that day. The latest delayed price is $1.91. Relative volume is exceptionally heavy at 6.0x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Peptides covered
- 6 peptides
- Commercial supply agreement
- Planned dispensing start
- November 2026
- Corexa Pharmacy compounded peptide prescriptions
Historical Context
-
Outlined plans to contract suppliers and fill eligible peptide prescriptions after a proposed FDA interim policy.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
api technical
bulk drug substance technical
3pl technical
503a regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, FL / ACCESS Newswire / November 2, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company")(NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that its pharmacy-focused subsidiary Corexa Health has entered into an agreement for commercial supply to bulk drug substance and API of six (6) peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, together the "Six Peptides") recommended by the U.S. Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee (PCAC) at its July 23-24, 2026 meeting. Corexa Pharmacy intends to begin dispending compliant compounded peptide prescriptions for patients in November 2026.
DataMEDS intends to leverage the Health Lives Here mobile application to help collect and report safety data, in accordance with U.S. Health and Human Services' (HHS) Enforcement Discretion Policy (EDP) published in the Federal Register on October 30, 2026. The U.S. compounding pharmacy market is expected to grow from
"HHS' recent policy changes allow Corexa Pharmacy to dispense compounded versions of these Six Peptides and also allows our distribution division to leverage its third-party logistics (3PL) capabilities to help bulk drug substance and API to compliantly manage their supply via our strategically located warehouse in Lakeland, Florida," said Gerald Commissiong, Interim Co-CEO of DataMEDS. "Through relationships with emerging manufacturers of compliant drug substance or API, helping to improve access to the Six Peptides for the 503A compounding pharmacies within our network of 6,500+ independent pharmacies. This represents a significant opportunity for Corexa to give physicians a regulated, pharmacy-compounded option in place of the unregulated research-use-only products sold online. We believe that many gray market patients would prefer to purchase their peptides from a licensed pharmacy.
The Six Peptides are compounded drugs, are not FDA-approved and have not been evaluated by FDA for safety or efficacy.
About DataMEDS AI
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA-based commercial clinical molecular diagnostics laboratory focused on the ChemoFx® Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions. Learn more at https://datamedsai.com.
About Tollo Health
Tollo Health, LLC is a healthcare company commercializing proprietary medical foods and dietary supplements and, through TolloBio, developing biopharmaceutical candidates, alongside its Health Lives Here mobile application. Corexa Health, a subsidiary of DataMeds AI, Inc., distributes select Tollo Health medical foods and dietary supplements under a wholesale distribution arrangement.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, statements regarding FDA or HHS could change or withdraw the enforcement discretion policy; competition from unregulated research-use-only products; FDA's final decisions on the bulks list; state board of pharmacy rules; reliance on a single supplier and its quality; sterile compounding compliance; adverse events and product liability; physician prescribing demand; uptake in the pharmacy network; the launch timing (November 2026); the white-label arrangement and reliance on the partner pharmacy; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
DataMEDS AI Media Contact
James Lambert, Vice President, Rubenstein Public Relations
212.805.3024 | jlambert@rubensteinpr.com
DataMEDS AI Investor Contact
IR@datamedsai.com
SOURCE: DataMEDS AI, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which peptides does DataMEDS AI's commercial supply agreement cover?
The agreement covers BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. The FDA's Pharmacy Compounding Advisory Committee recommended these peptides at its July 23–24, 2026 meeting. The compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or efficacy.
When does DataMEDS AI plan to begin dispensing compounded peptide prescriptions?
Corexa Pharmacy intends to begin dispensing compliant compounded peptide prescriptions in November 2026. This is a planned start, not an announcement that dispensing has already begun.